Filters








106 Hits in 11.8 sec

Treatment of Breast Cancer Lytic Skeletal Metastasis Using a Model in Nude Rats [chapter]

Michael Zepp, Tobias J., Victoria Elazar, Jenny Peterschmitt, Rinat Lifshitz-Shovali, Hassan Adwan, Franz P., Gershon Golomb, Martin R.
2011 Breast Cancer - Current and Alternative Therapeutic Modalities  
In that case those bones with initially smaller or less frequent osteolytic lesions such as the femur could be left with a higher number of osteoblasts which would be able to recalcify osteolytic lesions  ...  Beyond that, in rats with overt lytic lesions, at days 60 -65 new bone formation was observed in the femur and tibia.  ...  It was found that the BSPII ASO had a response by the inhibition of metastasis, but it was somewhat less effective than OPN ASO in bone lysis reduction, when delivered by NP.  ... 
doi:10.5772/24269 fatcat:5jivxtvur5hpvefj3lntwauxce

CT-based handling and analysis of preclinical multimodality imaging data of bone metastases

Thomas J A Snoeks, Martin Baiker, Eric L Kaijzel, Boudewijn P F Lelieveldt, Clemens W G M Löwik
2012 BoneKEy Reports  
Conflict of Interest The authors declare no conflict of interest. ACKNOWLEDGMENTS This work has been supported by the Dutch Cancer Society Koningin Wilhelmina Fonds (grant UL2007-3801; TS).  ...  Osteolytic bone metastases were induced by intracardial injection of 1 × 10 6 MDA-MB231-BO2 cells (an osteolytic, bone-specific subclone of the MDA breast carcinoma cell line) in a 6-week-old nude mice  ...  Osteolytic bone metastases were induced by intracardial injection of 1 × 10 6 MDA-MB231-BO2 cells (an osteolytic, bone-specific subclone of the MDA breast carcinoma cell line) in a 6-week-old nude mice  ... 
doi:10.1038/bonekey.2012.79 pmid:23951472 pmcid:PMC3727760 fatcat:3oh5cds7trcefc5n7xooeenvci

Species-dependent extracranial manifestations of a brain seeking breast cancer cell line

Valerie De Meulenaere, Sara Neyt, Bert Vandeghinste, Pieter Mollet, Olivier De Wever, Elke Decrock, Luc Leybaert, Ingeborg Goethals, Christian Vanhove, Benedicte Descamps, Karel Deblaere, Aamir Ahmad
2018 PLoS ONE  
Metastatic brain tumors pose a severe problem in the treatment of patients with breast carcinoma.  ...  As the size of the rat brain allows improved in vivo imaging, we attempted to establish a rat model for breast cancer brain metastasis that allows follow-up by 7 tesla (7T) preclinical Magnetic Resonance  ...  Acknowledgments The MDA-MB-231br/eGFP cell line was a kind gift of Dr. P. Steeg from the National Cancer Institute, Bethesda.  ... 
doi:10.1371/journal.pone.0208340 pmid:30532191 pmcid:PMC6287854 fatcat:cn6nmhvdtfdanpwkjufe5snrpi

Fracture Risk Evaluation of Bone Metastases: A Burning Issue

Cyrille B. Confavreux, Hélène Follet, David Mitton, Jean Baptiste Pialat, Philippe Clézardin
2021 Cancers  
The centerpiece of the reflection lies in the fracture risk evaluation of bone metastasis to guide physician decision regarding physical activity, antiresorptive agent prescription, and local intervention  ...  A key mandatory step, since bone metastases may be asymptomatic and disseminated throughout the skeleton, is to identify the bone metastasis location by cartography, especially within weight-bearing bones  ...  Conflicts of Interest: The authors declare no conflict of interest for this review. The funders had no role in the design and in the writing of the manuscript.  ... 
doi:10.3390/cancers13225711 pmid:34830865 pmcid:PMC8616502 fatcat:hmemvymtebf4bmsceuqdwfnuae

Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein

Tobias Bäuerle, Jenny Peterschmitt, Heidegard Hilbig, Fabian Kiessling, Franz Armbruster, Martin Berger
2006 International Journal of Oncology  
Osteolytic lesions of the respective hind leg were detected by X-ray and CT analysis as well as by immunohistochemistry.  ...  In nude rats, preincubation of MDA-MB-231 GFP cells prior to inoculation (25-100 μg/ml) reduced the mean osteolytic lesion size to 22 T/C% after 90 days of observation (p<0.05).  ...  Bone lesions in the femur, tibia and fibula of a rat receiving anti-BSP and ErPC 3 are shown in Fig. 5 , lane VI.  ... 
doi:10.3892/ijo.28.3.573 fatcat:jckhz3arkvbt7oord5nrtrrm6m

Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway

J Yang, K Fizazi, S Peleg, C R Sikes, A K Raymond, N Jamal, M Hu, M Olive, L A Martinez, C G Wood, C J Logothetis, G Karsenty (+1 others)
2001 Cancer Research  
In contrast, the highly undifferentiated, bone-derived human prostate cancer cell line PC3 did not produce an osteoblastic reaction in vitro and induced osteolytic lesions in vivo.  ...  An in vitro model of bone metastases from prostate cancer was developed using a bicompartment coculture system of mouse osteoblasts and human prostate cancer cells.  ...  C, histological evidence of osteolytic lesions in the femur of a mouse injected with PC3 cells. Osteoclasts (arrows) are obvious at the tumor bone interface.  ... 
pmid:11454720 fatcat:yrpdwnklgbgavhvnh3luhw3hxq

Behavioral, Medical Imaging and Histopathological Features of a New Rat Model of Bone Cancer Pain

Louis Doré-Savard, Valérie Otis, Karine Belleville, Myriam Lemire, Mélanie Archambault, Luc Tremblay, Jean-François Beaudoin, Nicolas Beaudet, Roger Lecomte, Martin Lepage, Louis Gendron, Philippe Sarret (+1 others)
2010 PLoS ONE  
Bone metastases were visualized as early as day 8 by MRI (T 1 -Gd-DTPA) before pain detection.  ...  Breast or prostate cancer patients coping with bone metastases experience intractable pain, which affects their quality of life.  ...  Pelmus and Mongeau from the Service of Pathology of the CHUS for their contribution to the histological analysis. We also thank Yonjung Xiao for the mCT analyses of our bone samples.  ... 
doi:10.1371/journal.pone.0013774 pmid:21048940 pmcid:PMC2966439 fatcat:coudyanyxrechmk6vjg7dmkdry

A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone

L. Thibaudeau, A. V. Taubenberger, B. M. Holzapfel, V. M. Quent, T. Fuehrmann, P. Hesami, T. D. Brown, P. D. Dalton, C. A. Power, B. G. Hollier, D. W. Hutmacher
2014 Disease Models & Mechanisms  
Histological analysis revealed the presence of metastases with clear osteolysis in the newly formed bone.  ...  with breast cancer-induced RESOURCE ARTICLE bone lesions.  ...  Bogoevski for assisting with the slide scanning.  ... 
doi:10.1242/dmm.014076 pmid:24713276 pmcid:PMC3917251 fatcat:kbfzruqc7rgidlqdmvo64ylsvu

Dichotomic effects of clinically used drugs on tumor growth, bone remodeling and pain management

David André Barrière, Élora Midavaine, Louis Doré-Savard, Karyn Kirby, Luc Tremblay, Jean-François Beaudoin, Nicolas Beaudet, Jean-Michel Longpré, Roger Lecomte, Martin Lepage, Philippe Sarret
2019 Scientific Reports  
These findings also support the use of nabilone as an adjuvant therapy for bone metastases.  ...  Here, we used a female rat MRMT-1 model of breast cancer-induced bone pain to compare the effects of three drugs used clinically morphine, nabilone and zoledronate on tumor progression, bone remodeling  ...  Pain is a severe problem in patients copying with bone metastases.  ... 
doi:10.1038/s41598-019-56622-5 pmid:31882872 pmcid:PMC6934511 fatcat:34unamcaw5banmjelqakbjbea4

Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases

QI GUI, CHENGCHENG XU, DAPENG LI, LIANG ZHUANG, SHU XIA, SHIYING YU
2015 Molecular Medicine Reports  
The results suggested that urinary levels of NTx may predict the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases.  ...  Rats were implanted with intra-femur Walker 256 carcinoma cells or control solution, and were treated with either normal saline, zoledronic acid or paclitaxel on the 10th day following surgery.  ...  Paclitaxel, a chemotherapeutic drug, reduces the growth of osteolytic lesions and exhibits anti-tumor and anti-resorptive effects in bone metastases in rat models (6) .  ... 
doi:10.3892/mmr.2015.3948 pmid:26081451 pmcid:PMC4526072 fatcat:hosymvtqi5fgdmon3swsjvsbmm

Curcumin, but not curcumin-glucuronide, inhibits Smad signaling in TGFβ-dependent bone metastatic breast cancer cells and is enriched in bone compared to other tissues

Andrew G Kunihiro, Julia A Brickey, Jennifer B Frye, Paula B Luis, Claus Schneider, Janet L Funk
2019 Journal of Nutritional Biochemistry  
Breast cancer (BCa) bone metastases (BMETs) drive osteolysis via a feed-forward loop involving tumoral secretion of osteolytic factors (e.g., PTHrP) induced by bone-matrix-derived growth factors (e.g.,  ...  Compared to serum and other organs, free curcumin (both absolute and percentage of total) was significantly increased in bone, which was also a rich source of enzymatic deglucuronidation activity.  ...  The propensity of breast cancer to form osteolytic bone lesions appears to be driven by interactions between bone-metastatic tumor cells and the bone microenvironment [2] [3] [4] [5] .  ... 
doi:10.1016/j.jnutbio.2018.09.021 pmid:30393127 pmcid:PMC6296872 fatcat:b3uqlr4xgja6rmecfulm37ttoi

Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells

Hassan Adwan, Tobias J Bäuerle, Martin R Berger
2003 Cancer Gene Therapy  
Pre-exposure to the ASOs, but not to the NSO, inhibited formation of osteolytic metastasis in three of four (ASO-OPN-04, Po0.03) and two of four (ASO-BSPII-06) nude rats, and reduced metastasis lesions  ...  We conclude that downregulation of OPN and BSPII reduces colony formation of MDA-MB-231 cells and formation of osteolytic metastasis in nude rats.  ...  Acknowledgments The experiments described were performed within the framework of the DKFZ Heidelberg-MOS Israel cooperation in cancer research and one of the authors (HA) was funded by a grant from this  ... 
doi:10.1038/sj.cgt.7700659 pmid:14647232 fatcat:ruaon3deorhqpcbnkeh346czqa

Perspectives on molecular and anatomical imaging in drug discovery

Matthew D. Silva, Mac Johnson, Donna Cvet, Rob Robertson, Erik Kupperman, Corinne Reimer, Barbara Hibner, Sudeep Chandra
2005 BioTechniques  
The authors would like to gratefully acknowledge the valued contributions of the other members of the Imaging Sciences Group: Elizabeth Siebert, Melissa Saylor, and Yumin Zhang.  ...  and head of the animal showing the shoulder and head bone changes (Figure 2C ); and (iii) a 3-D rendered image of the animal leg, demonstrating the osteolytic lesion in the distal femur (Figure 2D )  ...  Finally, the BLI data points to a femoral tumor, and the microCT image of that region confirms an osteolytic lesion of the distal femur (D). CT, computerized tomography. Figure 3 . 3 Figure 3.  ... 
doi:10.2144/000112092 pmid:20158501 fatcat:gdc5faelpjgftktczbqj35d4ta

Inhibiting STAT3 in a murine model of human breast cancer-induced bone pain delays the onset of nociception

Katja Linher-Melville, Manu Sharma, Peter Nakhla, Elena Kum, Robert Ungard, Ji Park, David Rosa, Patrick Gunning, Gurmit Singh
2019 Molecular Pain  
Prior to sacrifice and at ethical end point, tumour-induced osteolytic lesions were radiographically assessed.  ...  human interleukin 6 levels detected in the host circulation.  ...  Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.  ... 
doi:10.1177/1744806918823477 pmid:30799695 pmcid:PMC6329039 fatcat:motmci64m5ap7jl6u2lgyti7o4

The nonreceptor protein tyrosine kinase Src participates in every step of cancer-induced bone pain

Yaoyuan Li, Yanju Bao, Honggang Zheng, Yinggang Qin, Baojin Hua
2021 Biomedicine and Pharmacotherapy  
Src protein tyrosine kinase is mainly composed of six domains, with two states of automatic inhibition and activation.  ...  Src is beneficial to the growth and proliferation of tumor cells, and it can promote the metastases of primary tumors to bone.  ...  In an animal experiment of bone metastasis of PC-3 prostate cancer cells, compared with treatment with the specific SFK inhibitor saracatinib, the control group showed more severe osteolytic lesions.  ... 
doi:10.1016/j.biopha.2021.111822 pmid:34147901 fatcat:anvi5dvatbdlppxcchievdpjne
« Previous Showing results 1 — 15 out of 106 results